Drug Trial Radar · NCT03736967
Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Nov 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
206
Actual
Start
Nov 12, 2018
Primary completion
Mar 13, 2020
Study completion Jul 28, 2020
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- Collaborators
- Sanofi
- First posted
- Nov 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the efficacy of REGN3500 monotherapy compared with placebo treatment in adult patients with moderate-to-severe Atopic dermatitis (AD). Secondary Objectives are to: * Evaluate the efficacy of REGN3500 in combination with dupilumab compared with placebo treatment in adult patients with moderate-to-severe AD * Assess the safety, tolerability, and immunogenicity of subcutaneous (SC) doses of REGN3500 monotherapy and REGN3500 in combination with dupilumab in adult patients with moderate-to-severe AD * Evaluate the Pharmacokinetic (PK) of REGN3500 monotherapy and REGN3500 in combination with dupilumab in adult patients with moderate-to-severe AD
Conditions
- Atopic Dermatitis
Interventions
REGN3500Drug
Administered subcutaneous (SC) every 2 weeks (q2w)
DupilumabDrug
Administered SC q2w
REGN3500 + Dupilumab ComboDrug
Administered SC q2w
PlaceboDrug
Administered SC q2w
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16Time frame: Week 16
Locations
66 sites in 7 countries. Site status is shown where the registry gives one.
Regeneron Research Site
Phoenix, Arizona
Regeneron Research Site
Fountain Valley, California
Regeneron Research Site
Long Beach, California
Regeneron Research Site
Los Angeles, California
Regeneron Research Site
Los Angeles, California
Regeneron Research Site
Sacramento, California
Regeneron Research Site
Davie, Florida
Regeneron Research Site
Sandy Springs, Georgia
Regeneron Research Site
Rockville, Maryland
Regeneron Research Site
Bay City, Michigan
Regeneron Research Site
Saint Joseph, Michigan
Regeneron Research Site
Troy, Michigan
Regeneron Research Site
Forest Hills, New York
Regeneron Research Site
New York, New York
Regeneron Research Site
New York, New York
Regeneron Research Site
The Bronx, New York
Regeneron Research Site
High Point, North Carolina
Regeneron Research Site
Norman, Oklahoma
Regeneron Research Site
Portland, Oregon
Regeneron Research Site
Pittsburgh, Pennsylvania
Regeneron Research Site
Arlington, Texas
Regeneron Research Site
Richmond, Virginia
Regeneron Research Site
Anderlecht, Belgium
Regeneron Research Site
Antwerp, Belgium
Regeneron Research Site
Brussels, Belgium
Regeneron Research Site
Brussels, Belgium
Regeneron Research Site
Liège, Belgium
Regeneron Research Site
Loverval, Belgium
Regeneron Research Site
Brno, Czechia
Regeneron Research Site
Pardubice, Czechia
Regeneron Research Site
Prague, Czechia
Regeneron Research Site
Prague, Czechia
Regeneron Research Site
Bad Bentheim, Germany
Regeneron Research Site
Berlin, Germany
Regeneron Research Site
Halle, Germany
Regeneron Research Site
Hamburg, Germany
Regeneron Research Site
Hamburg, Germany
Regeneron Research Site
Hanau, Germany
Regeneron Research Site
Leipzig, Germany
Regeneron Research Site
Lübeck, Germany
Showing 40 of 66 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.